Introduction:

The objective of this article was to analyze the financial costs of antibiotic therapy against bacterial resistance in a public hospital of high complexity located in the Agreste region of Pernambuco.

Method:

It was performed a descriptive, retrospective and cross-sectional study based on data collected from Hospital Infection Control Commission (CCIH) and the Pharmaceutical Supply Center (CAF) of the investigated hospital. It was obtained by a structured instrument of data collection and the period analysed was from January to December 2016.

Results:

The main clinical samples with presence of bacterial multiresistance were blood, urine and tracheal secretion, with a higher prevalence of the following bacteria: Staphylococcus aureus(23,08%), Coagulase-negative Staphylococcus(26,15%), Citrobactersp. (19,23%), Enterobactersp. (10,77%) and Pseudomonassp (7,69%). Faced to the multiresistance presented, the most common antibiotics used in the treatment were: vancomycin (21,7%), piperacillin-tazobactam (24,55%), ampicillin-sulbactam (10,4%), cefepime (18,43%) and meropenem (58,5%). The presence of resistant bacteria was a cause of increased costs in the treatment of patients. According to this study, the antibiotic therapy listed above generated a cost of R$ 83.298,83 and 49% of hospital death in 2016.

Conclusion:

The prevention, through of policies related to the control and rational use of antimicrobials, is fundamental in the fight against hospital infections caused by multiresistant bacteria.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )